The U.K.’s National Health Service (NHS) is expected to block the use of another Alzheimer’s treatment, Eli Lilly And Co‘s (NYSE:LLY) donanemab, following the recent rejection of Biogen Inc‘s (NASDAQ:BIIB) Leqembi (lecanemab) by the National Institute for Health and Care Excellence (NICE).
Although donanemab has shown greater effectiveness in slowing cognitive decline than lecanemab, experts believe it will face the same fate due to safety concerns and high costs.
Also Read: Eli Lilly’s Alzheimer’s Therapy’s Broad Label Reflects Regulatory Confidence in Anti-Amyloid Antibodies: Analyst.
Donanemab showed its ability to slow Alzheimer’s progression by 35%, compared to lecanemab’s 27%.
However, trials also revealed significant risks: one in three ...
